A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis

Journal of Medical Economics

Volumn 18, Issue 11, 2015, Pages 944-953

  Kip, Michelle M A ^a   Kusters, Ron ^a,b   Ijzerman, Maarten J ^a,c   Steuten, Lotte M G ^c,d  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c PANAXEA B V   (Netherlands)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Antibiotics; Cost effectiveness; Intensive care; Procalcitonin; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ADULT; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE MARKER; DRUG EXPOSURE; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; INTENSIVE CARE; PRACTICE GUIDELINE; SENSITIVITY ANALYSIS; SEPSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; ARTIFICIAL VENTILATION; BLOOD; COST BENEFIT ANALYSIS; DIALYSIS; ECONOMICS; INTENSIVE CARE UNIT; LENGTH OF STAY; NETHERLANDS; STATISTICS AND NUMERICAL DATA;

ALGORITHMS; ANTI-BACTERIAL AGENTS; BIOMARKERS; CALCITONIN; COST-BENEFIT ANALYSIS; DECISION TREES; DIALYSIS; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; NETHERLANDS; PROTEIN PRECURSORS; RESPIRATION, ARTIFICIAL; SEPSIS;

EID: 84945134862     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1064934     Document Type: Article

References (44)

1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2012;41:580-637
2. Marik PE. Don't miss the diagnosis of sepsis! Crit Care 2014;18:529
3. Carlet J. Rapid diagnostic methods in the detection of sepsis. Infect Dis Clin North Am 1999;13:483-94
4. Schuetz P, Chiappa V, Briel M, et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011;171:1322-31
5. Wenzel RP, Edmond MB. Managing antibiotic resistance. N Engl J Med 2000;343:1961-3
6. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36:941-52
7. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009;394:221-6
8. Hochreiter M, Kohler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009;13:R83
9. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008;177:498-505
10. Matthaiou DK, Ntani G, Kontogiorgi M, et al. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 2012;38:940-9
11. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011;53:379-87
12. Tang H, Huang T, Jing J, et al. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37:497-507
13. Wilke MH, Grube RF, Bodmann KF. The use of a standardized PCT-algorithm reduces costs in intensive care in septic patients - a DRG-based simulation model. Eur J Med Res 2011;16:543-8
14. Harrison M, Collins CD. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis? Infect Control Hosp Epidemiol 2015;36:265-72
15. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. London: The Cochrane Collaboration, 2011. http://handbook.cochrane.org/. Accessed June 12, 2012
17. Adrie C, Alberti C, Chaix-Couturier C, et al. Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. J Crit Care 2005;20:46-58
18. Shapiro NI, Wolfe RE, Wright SB, et al. Who needs a blood culture? A prospectively derived and validated prediction rule. J Emerg Med 2008;35:255-64
19. Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010;138:121-9
20. Stocker M, Fontana M, El Helou S, et al. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal earlyonset sepsis: prospective randomized intervention trial. Neonatology 2010;97:165-74
21. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302:1059-66
22. van Nieuwkoop C, Bonten TN, van't Wout JW, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 2010;14:R206
23. Nederlandse Zorgautoriteit. Bijlage 1 bij tariefbeschikking TB/CU-7041-03. 2013. http://www.nza.nl/98174/139255/654366/bijlagemap/TB-CU-7041-03-bijlage1.pdf. Accessed November 26, 2013
24. DBC Onderhoud. Gebruikersdocument uitlevering deel 2: verantwoording tariefswijzigingen. 2011. http://www.nza.nl/104107/138040/bijlagemap/Bijlage-2-bij-release-RZ13a-Gebruikersdocument-uitlevering-deel-2.pdf. Accessed November 29, 2013
25. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek; Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Rotterdam: Institute for Medical Technology Assessment, Erasmus University, 2010
26. Vandijck DM, Depaemelaere M, Labeau SO, et al. Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents 2008;31:161-5
27. Centraal Bureau voor de Statistiek. Consumentenprijzen;prijsindex 2006 = 100. The Hague and Heerlen: Centraal Bureau voor de Statistiek, 2014. http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=71311NED&D1 =0&D2=0&D3=64,77,90,103,116,129,142,155,168,181,194,219,232, 245&VW=T. Accessed February 18, 2014
28. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
29. Deliberato RO, Marra AR, Sanches PR, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis 2013;76:266-71
30. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463-74
31. Annane D, Maxime V, Faller JP, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open 2013;3
32. VMS veiligheidsprogramma. Voorkomen van lijnsepsis en behandeling van ernstige sepsis. The Hague: VSMzorg.nl, 2013. http://www.vsmzorg.nl/Themas/Sepsis. Accessed August 8, 2014
33. Hohn A, Schroeder S, Gehrt A, et al. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infect Dis 2013;13:158
34. European Centre for Disease Prevention and Control. Antimicrobial resistance interactive database. Solna: European Centre for Disease Prevention and Control, 2012. http://www.ecdc.europa.eu/en/activities/surveillance/EARSNet/Pages/index.aspx. Accessed May 25, 2014
35. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis occurrence in acutely ill patients. Crit Care Med 2006;34:344-53
36. Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011;53:42-8
37. Lye DC, Earnest A, Ling ML, et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect 2012;18:502-8
38. Mitchell BG, Gardner A, Barnett AG, et al. The prolongation of length of stay because of Clostridium difficile infection. Am J Infect Control 2014;42:164-7
39. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009;49:1175-84
40. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000;162:505-11
41. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-98
42. Heyland DK, Johnson AP, Reynolds SC, et al. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011;39:1792-9
43. Organisation for Economic Cooperation and Development. Health at a Glance: Europe. Paris: OECDiLibrary, 2014. http://www.oecd-ilibrary.org/socialissues-migration-health/health-at-a-glance-europe-23056088;jsessionid =1wladsmo5vt8l.x-oecd-live-02. Accessed June 5, 2015
44. Saeed K, Dryden M, Bourne S, et al. Reduction in antibiotic use through procalcitonin testing in patients in the medical admission unit or intensive care unit with suspicion of infection. J Hosp Infect 2011;78:289-92